Novartis
NEWS
Narasimhan takes over the role of CEO in February as current CEO Joe Jimenez retires.
Life sciences professionals don’t have to look far for opportunity in Genetown.
Novartis has found its new chief of oncology.
2017 was the second-best year for FDA approvals since 1996.
A look at the lucky drugs that have been hailed a breakthrough by the FDA.
A Novartis drug approved as a second-line treatment for a blood disorder snagged the FDA’s Breakthrough Therapy Designation as a first-line defense.
The company said the Breakthrough Therapy Designation is based on positive results from the Phase III MONALEESA-7 trial.
Ultragenyx CEO Emil Kakkis said the sale of the PRV will provide the company with an “important source of non-dilutive capital” that will be used to advance the company’s pipeline of rare and ultra-rare therapies.
Bruno Strigini, the CEO of Novartis Oncology, plans to exit the company’s Executive Committee by Dec. 31, 2017, and leave entirely in early 2018.
JOBS
IN THE PRESS